Join us for the 4th annual AUA–IBCG Bladder Cancer Forum, featuring rapid-fire debates on key controversies in contemporary bladder cancer management. IBCG members from around the world will present both sides of pressing clinical questions, offering diverse perspectives and expert insights in a fast-paced, engaging format.  

The IBCG25 retreat will bring together global leaders in bladder cancer to advance two high-impact initiatives: • Biomarkers in Urothelial Cancer: Focused on identifying best practices for biomarker discovery and clinical application—from diagnosis and surveillance to treatment and trial endpoints. • IBCG Bladder Toxicity Index (IBCG-BTx): A comprehensive framework to measure bladder-specific toxicity across therapies, including radiation, immunotherapy, and surgery. This year's meeting will feature collaborative working sessions, invited presentations, and contributions from industry and advocacy partners. More details to follow.